Outlook Therapeutics Inc (OTLK)
7.98
+0.65
(+8.87%)
USD |
NASDAQ |
May 20, 14:34
Outlook Therapeutics Research and Development Expense (Quarterly): 13.51M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 13.51M |
| December 31, 2023 | 4.529M |
| September 30, 2023 | 4.944M |
| June 30, 2023 | 11.10M |
| March 31, 2023 | 0.5449M |
| December 31, 2022 | 9.862M |
| September 30, 2022 | 8.990M |
| June 30, 2022 | 11.25M |
| March 31, 2022 | 12.22M |
| December 31, 2021 | 9.872M |
| September 30, 2021 | 9.935M |
| June 30, 2021 | 8.545M |
| March 31, 2021 | 8.529M |
| December 31, 2020 | 11.95M |
| September 30, 2020 | 7.623M |
| June 30, 2020 | 8.488M |
| March 31, 2020 | 4.383M |
| December 31, 2019 | 5.847M |
| September 30, 2019 | 4.493M |
| Date | Value |
|---|---|
| June 30, 2019 | 4.394M |
| March 31, 2019 | 6.498M |
| December 31, 2018 | 8.421M |
| September 30, 2018 | 7.149M |
| June 30, 2018 | 5.796M |
| March 31, 2018 | 5.156M |
| December 31, 2017 | 0.4024M |
| September 30, 2017 | 2.059M |
| June 30, 2017 | 4.240M |
| March 31, 2017 | 4.199M |
| December 31, 2016 | 13.31M |
| September 30, 2016 | 4.212M |
| June 30, 2016 | 12.02M |
| March 31, 2016 | 4.138M |
| December 31, 2015 | 12.73M |
| September 30, 2015 | 13.20M |
| June 30, 2015 | 9.681M |
| March 31, 2015 | 10.15M |
| December 31, 2014 | 5.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.5449M
Minimum
Mar 2023
13.51M
Maximum
Mar 2024
8.050M
Average
8.537M
Median
Research and Development Expense (Quarterly) Benchmarks
| Cutera Inc | 5.001M |
| Actinium Pharmaceuticals Inc | 6.635M |
| GT Biopharma Inc | 1.357M |
| Karyopharm Therapeutics Inc | 35.42M |
| Marinus Pharmaceuticals Inc | 24.12M |